Artax Biopharma

Jan 22, 2025

Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study

Oct 03, 2024

Artax Biopharma to present first-in-class Nck modulator mechanism of action and Phase 1 data at the ACR Annual Meeting

Aug 13, 2024

Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158

Aug 06, 2024

Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024

Feb 13, 2024

Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158

Jan 04, 2024

Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 Year

Sep 17, 2020

Artax Biopharma Announces Issuance of U.S. Composition of Matter Patent for Autoimmune Disease Program AX-158

Jun 24, 2020

Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158

Jun 04, 2020

Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy

May 13, 2020

Artax Biopharma Appoints Joseph Lobacki as Chief Executive Officer, Announces Expanded Management Team